Tier 3 — preclinical

Supplementing Glycine and N-acetylcysteine (GlyNAC) in Aging HIV Patients Improves Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Endothelial Dysfunction, Insulin Resistance, Genotoxicity, Strength, and Cognition: Results of an Open-Label Clinical Trial

Premranjan Kumar, Chun Liu, James W Suliburk, Charles G Minard, Raja Muthupillai, Shaji Chacko, Jean W Hsu, Farook Jahoor, Rajagopal V Sekhar
Biomedicines 2020 8(10):390

Bibliography

PubMed
PMID 33007928
PubMed Central
PMC7601820
DOI
10.3390/biomedicines8100390
Funding
Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
Competing interests
Competing-interest disclosure was not located in the indexed record reviewed; consult the source publication for the full declaration.

Study snapshot

DesignOpen-label pilot study
ModelHuman
Sample8 older adults with HIV plus 8 comparison participants
InterventionGlycine plus NAC
Duration12 weeks
EndpointsGlutathione; Oxidative stress; Mitochondrial function; Metabolic and functional outcomes

What the study showed, in plain terms

Pilot GlyNAC study in older people living with HIV, a population with substantial oxidative and metabolic stress.

Key findings

Reported improvements across several glutathione, mitochondrial and functional measures.

What this study can and cannot tell us

Very small open-label sample and disease-specific population; no NAC-only arm.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology